Candidiasis
Drug research and approvals for candidiasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 25 studies of candidiasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, FDA has 2 approved and 5 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 25
- Trials authorized in Canada: 3
- FDA orphan approvals: 2
- EU medicines: 6
Recruiting Now
Newest start dates first, of 25 recruiting on ClinicalTrials.gov ↗- Biweekly Long-term Occidiofungin Study for Suppression of Mycotic RecurrenceNCT07521137 · Phase 2 · Sano Chemicals Inc · starts Jun 4, 2026
- Large Algorithm Setting and Validation StudyNCT07607470 · Not reported · Nanopath, Inc · starts Jun 3, 2026
- Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal CandidiasisNCT07603895 · Not applicable · Bioithas SL · starts May 25, 2026
- The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility StudyNCT05434104 · Not applicable · Guy's and St Thomas' NHS Foundation Trust · starts Apr 16, 2026
- Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal InfectionNCT07130799 · Not reported · Central Hospital, Nancy, France · starts Nov 14, 2025
- Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant OutcomesNCT05908682 · Not reported · GlaxoSmithKline · starts Nov 12, 2025
- Randomized Stepped Wedge Study of Emapalumab in APECED EnteritisNCT07202598 · Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Nov 12, 2025
- Multi-Gyn FemiTotal for the Treatment and Prevention of Vulvovaginal Candidiasis Symptoms and Bacterial VaginosisNCT07234786 · Not applicable · Karo Pharma AB · starts Oct 22, 2025
- One-stage Exchange in Candida Periprosthetic Infection a Suitable Way to goNCT07303101 · Not reported · University Hospital, Strasbourg, France · starts May 28, 2025
- Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)NCT06983041 · Not applicable · Coologics, Inc · starts May 22, 2025
Drug Pipeline
14 approved, 2 in phase 3, 2 in phase 2; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Fluconazole, Anidulafungin, Amphotericin b, Caspofungin, Micafungin, Voriconazole, Clotrimazole, Itraconazole, Nystatin, Flucytosine, Griseofulvin, Posaconazole, Ciclopirox, Rezafungin
- Metronidazole
- Phase 3 DNA inhibitor
- Tinidazole
- Phase 3 DNA disrupting agent
- Prednicarbate
- Phase 2 Glucocorticoid receptor agonist
- Octenidine
- Phase 2 Antiseptic
How Its Trials Ended
288 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 65 whose ending is known, 52% met their primary endpoint, 8% missed it and 40% stopped early.
- Completed, result not reported16156%
- Met its primary endpoint3412%
- Ongoing3412%
- Status unknown2810%
- Stopped: other or unclear145%
- Stopped: enrollment or feasibility124%
- Missed its primary endpoint52%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Oct 30, 2023 | Phase 1 single centre, open-labeled clinical trial to evaluate the safety and tolerability of topical nitric oxide releasing mouthwash (norm) for the…Nitric oxide | Sanotize Research & Development Corp | Closed |
| Feb 7, 2023 | A phase 3, multicenter, prospective, randomized, double-blind study of two treatment regimens for candidemia and/or invasive candidiasis: intravenous…Ibrexafungerp (SCY-078) | Scynexis | Closed |
| Sep 12, 2018 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of vt-1161 oral capsules in the treatment of subjects with…Oteseconazole (VT-1161)/ fluconazole | Mycovia Pharmaceuticals | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Jul 16, 2026 | RezzayoIn adults and pediatric patients 12 years of age or older who have limited or no alternative options for the treatment of candidemia and… | Mundipharma GmbH | Approved |
| Mar 22, 2023 | RezzayoIn patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis | Mundipharma GmbH | Approved |
| Mar 15, 2026 | Triterpenoid antifungalTreatment of invasive candidiasis | SCYNEXIS, Inc. | Designated |
| Nov 1, 2021 | MiltefosineTreatment invasive candidiasis | Profounda, lnc. | Designated |
| Oct 19, 2016 | FosmanogepixTreatment of invasive candidiasis | Basilea Pharmaceutica Ltd, Allschwil | Designated |
| Oct 20, 2014 | Isavuconazonium sulfateTreatment of invasive candidiasis/candidemia | Astellas Pharma Global Development, Inc. | Designated |
| Jun 27, 1996 | Amphotericin B lipid complexTreatment of invasive candidiasis. | The Liposome Company, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Dec 22, 2023 | RezzayoRezafungin · orphan | Mundipharma GmbH | EMA ↗ |
| Apr 25, 2008 | MycamineMicafungin | Sandoz Pharmaceuticals d.d. | EMA ↗ |
| Sep 20, 2007 | EcaltaAnidulafungin | Pfizer Europe MA EEIG | EMA ↗ |
| Oct 25, 2005 | NoxafilPosaconazole | Merck Sharp and Dohme B.V | EMA ↗ |
| Mar 19, 2002 | VfendVoriconazole | Pfizer Europe MA EEIG | EMA ↗ |
| Oct 23, 2001 | Cancidas (previously Caspofungin MSD)Caspofungin | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA